FDA Approves First Gene Therapy for Adults With Hemophilia B
Benefits include decreased need for routine factor IX replacement prophylaxis and reduction in annualized bleeding rate
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.